APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vectors and Plasmid DNA Manufacturing

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.

Selected research

Market Outlook & Growth Opportunities

Global Viral Vectors and Plasmid DNA Manufacturing Market Outlook and Growth Opportunities 2026

21 December 2025202 pages

Choose your research edition.

Industry ResearchViral Vectors and Plasmid DNA Manufacturing Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vectors and Plasmid DNA Manufacturing Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Viral Vectors and Plasmid DNA Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vectors and Plasmid DNA Manufacturing Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vectors and Plasmid DNA Manufacturing Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.

Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.

North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.

Read the full market overview

In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.

This report provides an overview of the global Viral Vectors and Plasmid DNA Manufacturing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vectors and Plasmid DNA Manufacturing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vectors and Plasmid DNA Manufacturing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Vectors and Plasmid DNA Manufacturing market.

Viral Vectors and Plasmid DNA Manufacturing Segment by Company

BioReliance

Cobra Biologics

Oxford BioMedica

UniQure

FinVector

MolMed

MassBiologics

Richter-Helm

FUJIFILM Diosynth Biotechnologies

Lonza

Aldevron

Eurogentec

Cell and Gene Therapy Catapult

Biovian

Thermo Fisher Scientific (Brammer Bio)

VGXI

PlasmidFactory

Viral Vectors and Plasmid DNA Manufacturing Segment by Type

Plasmid DNA

Viral Vectors

Viral Vectors and Plasmid DNA Manufacturing Segment by Application

Cancers

Inherited Disorders

Viral Infections

Others

Viral Vectors and Plasmid DNA Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Vectors and Plasmid DNA Manufacturing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Viral Vectors and Plasmid DNA Manufacturing key companies, revenue, market share, and recent developments.

3. To split the Viral Vectors and Plasmid DNA Manufacturing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Viral Vectors and Plasmid DNA Manufacturing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Vectors and Plasmid DNA Manufacturing significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Vectors and Plasmid DNA Manufacturing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors and Plasmid DNA Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vectors and Plasmid DNA Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors and Plasmid DNA Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vectors and Plasmid DNA Manufacturing industry.

Chapter 3: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Viral Vectors and Plasmid DNA Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Viral Vectors and Plasmid DNA Manufacturing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Vectors and Plasmid DNA Manufacturing Industry Trends Table 2. Viral Vectors and Plasmid DNA Manufacturing Industry Drivers Table 3. Viral Vectors and Plasmid DNA Manufacturing Industry Opportunities and Challenges Table 4. Viral Vectors and Plasmid DNA Manufacturing Industry Restraints Table 5. Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Share by Company (2021-2026) Table 7. Global Viral Vectors and Plasmid DNA Manufacturing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Viral Vectors and Plasmid DNA Manufacturing Key Company Manufacturing Base & Headquarters Table 9. Global Viral Vectors and Plasmid DNA Manufacturing Company, Product Type & Application Table 10. Global Viral Vectors and Plasmid DNA Manufacturing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Viral Vectors and Plasmid DNA Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Plasmid DNA Table 15. Significant Companies of Viral Vectors Table 16. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type (2021-2026) Table 20. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancers Table 22. Significant Companies of Inherited Disorders Table 23. Significant Companies of Viral Infections Table 24. Significant Companies of Others Table 25. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application (2021-2026) Table 29. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application (2027-2032) Table 30. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Region (2021-2026) Table 33. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Region (2027-2032) Table 35. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Market Share by Country (2021-2026) Table 38. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Market Share by Country (2027-2032) Table 40. BioReliance Company Information Table 41. BioReliance Business Overview Table 42. BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 44. BioReliance Recent Development Table 45. Cobra Biologics Company Information Table 46. Cobra Biologics Business Overview Table 47. Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 49. Cobra Biologics Recent Development Table 50. Oxford BioMedica Company Information Table 51. Oxford BioMedica Business Overview Table 52. Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 54. Oxford BioMedica Recent Development Table 55. UniQure Company Information Table 56. UniQure Business Overview Table 57. UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 59. UniQure Recent Development Table 60. FinVector Company Information Table 61. FinVector Business Overview Table 62. FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 64. FinVector Recent Development Table 65. MolMed Company Information Table 66. MolMed Business Overview Table 67. MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 69. MolMed Recent Development Table 70. MassBiologics Company Information Table 71. MassBiologics Business Overview Table 72. MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 74. MassBiologics Recent Development Table 75. Richter-Helm Company Information Table 76. Richter-Helm Business Overview Table 77. Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 79. Richter-Helm Recent Development Table 80. FUJIFILM Diosynth Biotechnologies Company Information Table 81. FUJIFILM Diosynth Biotechnologies Business Overview Table 82. FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 84. FUJIFILM Diosynth Biotechnologies Recent Development Table 85. Lonza Company Information Table 86. Lonza Business Overview Table 87. Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 89. Lonza Recent Development Table 90. Aldevron Company Information Table 91. Aldevron Business Overview Table 92. Aldevron Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 94. Aldevron Recent Development Table 95. Eurogentec Company Information Table 96. Eurogentec Business Overview Table 97. Eurogentec Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 99. Eurogentec Recent Development Table 100. Cell and Gene Therapy Catapult Company Information Table 101. Cell and Gene Therapy Catapult Business Overview Table 102. Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 104. Cell and Gene Therapy Catapult Recent Development Table 105. Biovian Company Information Table 106. Biovian Business Overview Table 107. Biovian Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 109. Biovian Recent Development Table 110. Thermo Fisher Scientific (Brammer Bio) Company Information Table 111. Thermo Fisher Scientific (Brammer Bio) Business Overview Table 112. Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 114. Thermo Fisher Scientific (Brammer Bio) Recent Development Table 115. VGXI Company Information Table 116. VGXI Business Overview Table 117. VGXI Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 119. VGXI Recent Development Table 120. PlasmidFactory Company Information Table 121. PlasmidFactory Business Overview Table 122. PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 123. PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product Portfolio Table 124. PlasmidFactory Recent Development Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Viral Vectors and Plasmid DNA Manufacturing Product Image Figure 2. Global Viral Vectors and Plasmid DNA Manufacturing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vectors and Plasmid DNA Manufacturing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Plasmid DNA Image Figure 8. Viral Vectors Image Figure 9. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type (2021-2032) Figure 12. Cancers Image Figure 13. Inherited Disorders Image Figure 14. Viral Infections Image Figure 15. Others Image Figure 16. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application (2021-2032) Figure 19. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Plasmid DNA
  • Viral Vectors
Applications
  • Cancers
  • Inherited Disorders
  • Viral Infections
  • Others
Companies covered
  • BioReliance
  • Cobra Biologics
  • Oxford BioMedica
  • UniQure
  • FinVector
  • MolMed
  • MassBiologics
  • Richter-Helm
  • FUJIFILM Diosynth Biotechnologies
  • Lonza
  • Aldevron
  • Eurogentec
  • Cell and Gene Therapy Catapult
  • Biovian
  • Thermo Fisher Scientific (Brammer Bio)
  • VGXI
  • PlasmidFactory

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Vectors and Plasmid DNA Manufacturing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Vectors and Plasmid DNA Manufacturing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
  1. 2.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
  2. 2.2 Viral Vectors and Plasmid DNA Manufacturing Industry Drivers
  3. 2.3 Viral Vectors and Plasmid DNA Manufacturing Industry Opportunities and Challenges
  4. 2.4 Viral Vectors and Plasmid DNA Manufacturing Industry Restraints
3 Viral Vectors and Plasmid DNA Manufacturing Market by Company
  1. 3.1 Global Viral Vectors and Plasmid DNA Manufacturing Company Revenue Ranking in 2025
  2. 3.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2021-2026)
  3. 3.3 Global Viral Vectors and Plasmid DNA Manufacturing Company Ranking (2024-2026)
  4. 3.4 Global Viral Vectors and Plasmid DNA Manufacturing Company Manufacturing Base and Headquarters
  5. 3.5 Global Viral Vectors and Plasmid DNA Manufacturing Company Product Type and Application
  6. 3.6 Global Viral Vectors and Plasmid DNA Manufacturing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Viral Vectors and Plasmid DNA Manufacturing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Viral Vectors and Plasmid DNA Manufacturing Market by Type
  1. 4.1 Viral Vectors and Plasmid DNA Manufacturing Type Introduction
  2. 4.1.1 Plasmid DNA
  3. 4.1.2 Viral Vectors
  4. 4.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type
  5. 4.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type (2021-2032)
5 Viral Vectors and Plasmid DNA Manufacturing Market by Application
  1. 5.1 Viral Vectors and Plasmid DNA Manufacturing Application Introduction
  2. 5.1.1 Cancers
  3. 5.1.2 Inherited Disorders
  4. 5.1.3 Viral Infections
  5. 5.1.4 Others
  6. 5.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application
  7. 5.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2021-2032)
  9. 5.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application (2021-2032)
6 Viral Vectors and Plasmid DNA Manufacturing Regional Value Analysis
  1. 6.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032)
  7. 6.3.2 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032)
  10. 6.4.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032)
  16. 6.6.2 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Country, 2025 VS 2032
7 Viral Vectors and Plasmid DNA Manufacturing Country-level Value Analysis
  1. 7.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Viral Vectors and Plasmid DNA Manufacturing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BioReliance
  2. 8.1.1 BioReliance Company Information
  3. 8.1.2 BioReliance Business Overview
  4. 8.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  6. 8.1.5 BioReliance Recent Developments
  7. 8.2 Cobra Biologics
  8. 8.2.1 Cobra Biologics Company Information
  9. 8.2.2 Cobra Biologics Business Overview
  10. 8.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  12. 8.2.5 Cobra Biologics Recent Developments
  13. 8.3 Oxford BioMedica
  14. 8.3.1 Oxford BioMedica Company Information
  15. 8.3.2 Oxford BioMedica Business Overview
  16. 8.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  18. 8.3.5 Oxford BioMedica Recent Developments
  19. 8.4 UniQure
  20. 8.4.1 UniQure Company Information
  21. 8.4.2 UniQure Business Overview
  22. 8.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  24. 8.4.5 UniQure Recent Developments
  25. 8.5 FinVector
  26. 8.5.1 FinVector Company Information
  27. 8.5.2 FinVector Business Overview
  28. 8.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  30. 8.5.5 FinVector Recent Developments
  31. 8.6 MolMed
  32. 8.6.1 MolMed Company Information
  33. 8.6.2 MolMed Business Overview
  34. 8.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  36. 8.6.5 MolMed Recent Developments
  37. 8.7 MassBiologics
  38. 8.7.1 MassBiologics Company Information
  39. 8.7.2 MassBiologics Business Overview
  40. 8.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  42. 8.7.5 MassBiologics Recent Developments
  43. 8.8 Richter-Helm
  44. 8.8.1 Richter-Helm Company Information
  45. 8.8.2 Richter-Helm Business Overview
  46. 8.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  48. 8.8.5 Richter-Helm Recent Developments
  49. 8.9 FUJIFILM Diosynth Biotechnologies
  50. 8.9.1 FUJIFILM Diosynth Biotechnologies Company Information
  51. 8.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
  52. 8.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  54. 8.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  55. 8.10 Lonza
  56. 8.10.1 Lonza Company Information
  57. 8.10.2 Lonza Business Overview
  58. 8.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  60. 8.10.5 Lonza Recent Developments
  61. 8.11 Aldevron
  62. 8.11.1 Aldevron Company Information
  63. 8.11.2 Aldevron Business Overview
  64. 8.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  66. 8.11.5 Aldevron Recent Developments
  67. 8.12 Eurogentec
  68. 8.12.1 Eurogentec Company Information
  69. 8.12.2 Eurogentec Business Overview
  70. 8.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  72. 8.12.5 Eurogentec Recent Developments
  73. 8.13 Cell and Gene Therapy Catapult
  74. 8.13.1 Cell and Gene Therapy Catapult Company Information
  75. 8.13.2 Cell and Gene Therapy Catapult Business Overview
  76. 8.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  78. 8.13.5 Cell and Gene Therapy Catapult Recent Developments
  79. 8.14 Biovian
  80. 8.14.1 Biovian Company Information
  81. 8.14.2 Biovian Business Overview
  82. 8.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  84. 8.14.5 Biovian Recent Developments
  85. 8.15 Thermo Fisher Scientific (Brammer Bio)
  86. 8.15.1 Thermo Fisher Scientific (Brammer Bio) Company Information
  87. 8.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
  88. 8.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  90. 8.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
  91. 8.16 VGXI
  92. 8.16.1 VGXI Company Information
  93. 8.16.2 VGXI Business Overview
  94. 8.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  95. 8.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  96. 8.16.5 VGXI Recent Developments
  97. 8.17 PlasmidFactory
  98. 8.17.1 PlasmidFactory Company Information
  99. 8.17.2 PlasmidFactory Business Overview
  100. 8.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue and Gross Margin (2021-2026)
  101. 8.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
  102. 8.17.5 PlasmidFactory Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst